Syneron Candela's PicoWay Gets FDA Clearance For Treatment Of Pigmented Lesions

(RTTNews) - Syneron Medical Ltd. (ELOS) announced that the PicoWay picosecond laser received U.S. Food and Drug Administration or FDA clearance for the treatment of pigmented lesions.

The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the U.S. late in the fourth quarter 2014.

The company noted that PicoWay incorporates picosecond (one trillionth of a second) pulse duration to generate an ultra-short pulse and very high peak power of laser energy on the skin. The high energy ultra-short picosecond laser pulse creates a strong photo-mechanical impact that optimizes fracturing of tattoo ink or pigmentation. The PicoWay Technology is integrated into a proven, reliable Candela platform which offers high reliability, superior performance and low cost of ownership.

The company also announced Health Canada clearance of the PicoWay picosecond laser for the treatment of pigmented lesions and tattoo removal. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay Technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos of all colors. The Health Canada clearance is for all tattoo colors: red, yellow and orange for the 532nm wavelength; black, brown, green, blue and purple for the 1064nm wavelength.

The launch of PicoWay in Canada will begin during the second quarter 2015, building on the launch of the product in the U.S. and other international markets during the fourth quarter 2014. The Company sells its products in Canada through its direct North American sales organization.